Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
87.4M
-
Number of holders
-
154
-
Total 13F shares, excl. options
-
79.5M
-
Shares change
-
+13.2M
-
Total reported value, excl. options
-
$663M
-
Value change
-
+$119M
-
Put/Call ratio
-
0.78
-
Number of buys
-
100
-
Number of sells
-
-59
-
Price
-
$8.34
Significant Holders of Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) as of Q3 2024
186 filings reported holding TERN - Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share as of Q3 2024.
Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) has 154 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 79.5M shares
of 87.4M outstanding shares and own 91% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (7.56M shares), Vivo Capital, LLC (6.9M shares), Soleus Capital Management, L.P. (6.22M shares), Deep Track Capital, LP (5.58M shares), BlackRock, Inc. (4.7M shares), CITADEL ADVISORS LLC (3.67M shares), VR Adviser, LLC (3.41M shares), VANGUARD GROUP INC (3.36M shares), Schonfeld Strategic Advisors LLC (3.29M shares), and Point72 Asset Management, L.P. (2.71M shares).
This table shows the top 154 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.